Abstract.
In this study, we hypothesize that anti-cytokeratin 18 (CK18) antibody and CK18:anti-CK18 immune complex increase in sera in patients with idiopathic pulmonary fibrosis (IPF). To prove the existence of anti-CK18 antibodies in patients' sera, bovine CK18 was stained with patients' sera using a Western blotting. In patients with IPF, anti-CK18 antibodies were clearly demonstrated in sera by Western blotting. Then, we tried to establish an enzyme-linked immunosorbent assay (ELISA) to quantify anti-CK18 antibodies and CK18:anti-CK18 immune complexes in sera of patients with IPF. Levels of anti-human CK18 antibodies in sera of patients with IPF (0.81 ± 0.31, mean ± SD) measured by ELISA were significantly high compared with that of normal volunteers (0.45 ± 0.06, p < 0.01). In addition, levels of CK18:anti-CK18 antibody complexes in patients' sera (0.64 ± 0.35, man ± SD) significantly increased compared with those of normal subjects (0.40 ± 0.10, p < 0.01). These results suggest that anti-CK18 antibody and its immune complex may have played a role in the process of lung injury in IPF.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Author information
Authors and Affiliations
Additional information
Accepted for publication 30 March 2000
Rights and permissions
About this article
Cite this article
Dobashi, N., Fujita, J., Murota, M. et al. Elevation of Anti-Cytokeratin 18 Antibody and Circulating Cytokeratin 18: Anti-Cytokeratin 18 Antibody Immune Complexes in Sera of Patients with Idiopathic Pulmonary Fibrosis. 178, 171–179 (2000). https://doi.org/10.1007/s004080000020
Issue Date:
DOI: https://doi.org/10.1007/s004080000020